There is no clinically established, FDA-validated dose of ipamorelin for general use in humans. This article does not provide a personal recommendation on „how much to take daily” for bodybuilding, fat loss, or any other purpose. What it does provide is an accurate description of doses actually used in existing controlled clinical studies, along with an honest explanation of why that dosing from a research context cannot be safely translated into a guide for self-administration.
What is the standard dose of Ipamorelin?
There is no standard, medically validated dosage for ipamorelin. It has never gone through a regulatory approval process that would establish it for any indication in any country. What exists instead are specific doses used in published clinical trials, administered under direct medical supervision for specific research purposes. In a foundational pharmacokinetic study in humans, healthy male volunteers received ipamorelin as a 15-minute intravenous infusion. It was tested at five distinct dose levels: 4.21, 14.02, 42.13, 84.27, and 140.45 nanomoles per kilogram of body weight. Researchers measured how the growth hormone response scaled across this range [1].
In a separate Phase 2 clinical trial evaluating ipamorelin for postoperative gastrointestinal recovery, patients received a fixed intravenous dose of 0.03 milligrams per kilogram of body weight. This was administered twice daily for up to seven days, or until hospital discharge [2].
These numbers reflect what clinical researchers used, via intravenous administration, under monitored hospital or research conditions. They are fundamentally different from a self-administered, at-home subcutaneous injection schedule. No study was designed to establish general consumer dosing.
Since no equivalent studies exist testing repeated self-administration for weeks or months under unmonitored conditions, this article does not translate these clinical numbers into a personal daily dosage recommendation. This is consistent with the approach used throughout this series for CJC-1295.
Dosage of Ipamorelin for fat loss and bodybuilding
No ipamorelin dose has been validated for fat loss or bodybuilding purposes in peer-reviewed literature. This gap is worth treating seriously, not as a mere technicality. As discussed in a previous article in this series, available animal studies on ipamorelin's effect on adipose tissue actually found something surprising. It increased fat pad weight and food intake in mice, via a mechanism that appeared independent of growth hormone itself. This is likely related to ipamorelin's activation of the appetite-stimulating ghrelin receptor [3]. This finding directly complicates the common assumption that any dose of ipamorelin would support fat loss. No human studies have tested a specific dose for this purpose to either confirm or refute this.
Similarly, no human studies have tested any dose of ipamorelin specifically for muscle growth or bodybuilding performance. The doses discussed above come from a pharmacokinetic study measuring hormonal response and a surgical recovery study. Neither of these was designed to test or measure changes in body composition over time.
Given this complete lack of outcome-based dosing data for these specific goals, any bodybuilding or fat loss dosing figures circulating in commercial or informal sources are not derived from clinical research. They should not be treated as validated.
How often should Ipamorelin be taken?
Published research offers real-world, albeit narrow, guidance on dosing frequency, again in a clinical rather than a consumer context. The post-operative recovery study used twice-daily intravenous dosing for a treatment duration of up to seven days. This schedule was chosen to align with the short-term medical goal of that specific study—to aid post-surgical recovery. This frequency is consistent with ipamorelin’s short pharmacokinetic profile. It has a half-life of approximately two hours and a single growth hormone pulse subsiding within about six hours after each dose, as established in foundational pharmacokinetic studies [1], [2].
This short duration of action is part of why multiple, closely spaced doses were used in this clinical trial. This contrasts with a long-acting compound like CJC-1295 with DAC, which was tested with weekly or bi-weekly dosing due to its multi-day half-life.
It is important to clearly state that this twice-daily regimen for surgical recovery was designed for a specific, seven-day clinical purpose under hospital supervision. No published studies have tested or validated a continuous, long-term dosing frequency—measured in weeks or months—for general use. Questions regarding how many days a week or how many weeks a person „may” take ipamorelin remain unanswered by the current clinical literature.
Why don't we provide a practical dosage recommendation?
Providing a specific self-administered dose—micrograms, milligrams, or injection units—would require inventing numbers unsupported by validated studies. Ipamorelin has no FDA or EMA-approved dosing protocol for general use. Existing clinical doses were administered intravenously under direct medical supervision for narrow research purposes, not as a template for continuous self-administered subcutaneous injection.
As discussed in earlier articles in this series regarding related compounds, reviews of this broader category of peptides have specifically noted something significant. The dosage, frequency, and duration of growth hormone secretagogue use remain undefined in the clinical literature, despite informal and commercial use having risen significantly [4].
Limitations of current evidence
The dosing numbers described in this article come from two specific clinical trial contexts. One is a pharmacokinetic dose-escalation study. The other is a surgical post-operative recovery study. Both used intravenous administration under medical supervision. Neither was designed to establish a general dosing protocol for self-administration [1], [2].
No human studies have tested any dose of ipamorelin specifically for fat loss or muscle building outcomes. Available animal data regarding fat metabolism actually raise questions about the fat loss premise commonly attributed to this compound [3].
Disclaimer
Ipamorelin is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body for any human use, and no standardized, medically validated dosing protocol exists for bodybuilding, fat loss, or any other purpose. It is not manufactured or sold under the quality and safety oversight applicable to approved pharmaceuticals. The dosing information in this article reflects only what has been used in controlled clinical trials, under direct medical supervision, and does not establish a safe or effective protocol for self-administration. This article is provided for general educational and informational purposes only, reflects the state of published scientific literature at the time of writing, and does not constitute medical advice. Nothing in this article should be interpreted as a recommendation for self-administration or used to guide personal dosing decisions.
References
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[3] Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and Biophysical Research Communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065
[4] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593